ArticleInfectious diseases & clinical microbiology2026
Serum Galectin-3 in Diabetic Foot Infections: A Case-Control Evaluation of Its Diagnostic and Severity-Grading Utility.
Article in Infectious diseases & clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Galectin-3 (Gal-3) is a galactose-binding lectin released from immune cells that modulates the immune response and plays a role in type 2 diabetes mellitus (DM) and related vascular complications. This study aimed to investigate the relationship between serum Gal-3 levels and infection and inflammatory processes among patients with type 2 DM, diabetic foot infection (DFI), and healthy controls. Materials and Methods: Patients with DFI, patients with type 2 DM without signs of infection, and healthy controls without comorbidities admitted to our clinic were included in the study. Serum Gal-3 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Data were analyzed using the Statistical Package for the Social Sciences (SPSS), version 21.0. Statistical significance was set at Results: Thirty-six patients with DFI, 24 patients with type 2 DM without signs of infection, and 24 healthy controls were included in the study. The median Gal-3 level was 232.54 pg/mL among patients with DFI, 209.14 pg/mL among patients with type 2 DM without infection, and 277.85 pg/mL among healthy group. No statistically significant difference in Gal-3 levels was found among the three groups ( Conclusion: In our study, Gal-3 levels did not differ significantly among patients with DFI, patients with type 2 DM without infection, and healthy controls. More comprehensive studies are needed to clarify the potential diagnostic and severity-assessment value of Gal-3 in DFI. Graphical Abstract: Graphical Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.